Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was in the spotlight after it rejected a second takeover bid by Cycle Group.

"Exelixis and MSD to trial cancer therapies together in clinical collaboration" was originally created and published by ...

Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

Veterinary technicians are crucial to pet healthcare and the demand and necessity for this key role has continued to increase post pet boom. However, 47% of pet owners are unaware of how impactful a ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive ...

On October 14, 2024, MRK announced a clinical development collaboration with Exelixis to evaluate the investigational drug ...

It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation ...

India on Thursday weighed in on the ongoing diplomatic spat with Canada by holding the Trudeau administration responsible for 'precipitating' the current diplomatic fallout while acknowledging the ...

The new law was pushed by the party of Giorgia Meloni, Italy’s conservative prime minister. By Emma Bubola The stiff penalty was the potentially final step in the stunning downfall of the ...